Verification evidence is still being completed.
Camurus
Lund, Sweden
- Verified lead
- Fredrik Tiberg
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- President and Chief Executive Officer
- 2026 technical specialization
- Long-Acting Drug Delivery and Specialty Pharmaceutical Development
- Review cycle
- May 2026
- Full address
- Rydbergs torg 4, 224 84 Lund, Sweden
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Camurus management team page confirming Fredrik Tiberg as CEO.
- Editorial note
- Camurus joins the Swedish directory layer with a current official executive disclosure and a clearly defined specialty-pharma operating profile.
Long-Acting Drug Delivery and Specialty Pharmaceutical Development
Clinical and commercial pharmaceutical quality systems, Specialty pharma operating controls
Camurus joins the Swedish directory layer with a current official executive disclosure and a clearly defined specialty-pharma operating profile.
Camurus
Long-Acting Drug Delivery and Specialty Pharmaceutical Development · Late-stage and commercial specialty pharma
Verified 14 Mar 2026 · 3 sources
Camurus joins the Swedish directory layer with a current official executive disclosure and a clearly defined specialty-pharma operating profile.
- Website
- camurus.com
- Company page
- Lead
- Fredrik Tiberg (verified ↗)
- Compliance
- GLP
- Last reviewed
- 14 Mar 2026 (3mo ago)
- Scale
- Late-stage and commercial specialty pharma
- Capabilities
- Long-Acting Drug Delivery · Specialty Pharma Development · Commercial Product Operations
- Founded
- 1991
- Headcount
- 51-200
Fredrik Tiberg
President and Chief Executive Officer
Official Camurus press release and footer contact naming Camurus AB at Rydbergs torg 4 in Lund.
Open sourceLate-stage and commercial specialty pharma
Lund, Sweden. Long-Acting Drug Delivery and Specialty Pharmaceutical Development. Review completed on 14 Mar 2026.
Swedish and EU pharmaceutical oversight
Clinical and commercial pharmaceutical quality systems, Specialty pharma operating controls
Long-Acting Drug Delivery and Specialty Pharmaceutical Development
Camurus joins the Swedish directory layer with a current official executive disclosure and a clearly defined specialty-pharma operating profile.
Camurus joins the Swedish directory layer with a current official executive disclosure and a clearly defined specialty-pharma operating profile.
Core capabilities
Primary declared technical activities and areas of operating focus.
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Declared infrastructure
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- VERIFIED ACTIVE 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Frequently asked questions
- Where is Camurus located?
- Camurus operates from Rydbergs torg 4, 224 84 Lund, Sweden, Lund, Sweden.
- Who runs Camurus?
- Camurus is led by Fredrik Tiberg, President and Chief Executive Officer. Verified 14 Mar 2026.
- What does Camurus do?
- Camurus joins the Swedish directory layer with a current official executive disclosure and a clearly defined specialty-pharma operating profile. Core capabilities: Long-Acting Drug Delivery, Specialty Pharma Development, Commercial Product Operations.
Related technical briefs
Briefs that name Lund as a covered market or city.
